First National Trust Co Has $14.62 Million Stake in Eli Lilly and Company (NYSE:LLY)

First National Trust Co lowered its stake in Eli Lilly and Company (NYSE:LLY) by 1.3% in the fourth quarter, Holdings Channel reports. The fund owned 25,081 shares of the company’s stock after selling 330 shares during the quarter. First National Trust Co’s holdings in Eli Lilly and Company were worth $14,620,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in LLY. Lipe & Dalton acquired a new position in Eli Lilly and Company during the 4th quarter worth approximately $26,000. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company during the 3rd quarter worth approximately $27,000. Legacy Financial Group LLC acquired a new position in Eli Lilly and Company during the 3rd quarter worth approximately $35,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company during the 3rd quarter worth approximately $36,000. Finally, Family CFO Inc acquired a new position in Eli Lilly and Company during the 3rd quarter worth approximately $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Citigroup upped their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Bank of America upped their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research report on Wednesday, February 21st. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Finally, The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Stock Down 2.8 %

NYSE LLY traded down $20.94 on Friday, hitting $734.97. 4,595,138 shares of the company were exchanged, compared to its average volume of 2,629,045. The company has a market cap of $698.52 billion, a PE ratio of 108.24, a PEG ratio of 1.46 and a beta of 0.37. Eli Lilly and Company has a 12 month low of $419.80 and a 12 month high of $800.78. The stock has a fifty day moving average of $761.06 and a 200-day moving average of $671.38. The company has a current ratio of 1.35, a quick ratio of 0.73 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue was up 26.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.62 earnings per share. As a group, analysts forecast that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.